FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136175145> ?p ?o ?g. }

• W3136175145 endingPage "524" @default.
• W3136175145 startingPage "510" @default.
• W3136175145 abstract "Although the majority of patients with metastatic non-small-cell lung cancer (mNSCLC) lacking a detectable targetable mutation will receive pembrolizumab-based therapy in the frontline setting, predicting which patients will experience a durable clinical benefit (DCB) remains challenging.Patients with mNSCLC receiving pembrolizumab monotherapy or in combination with chemotherapy underwent a 74-gene next-generation sequencing panel on blood samples obtained at baseline and at 9 weeks. The change in circulating tumor DNA levels on-therapy (molecular response) was quantified using a ratio calculation with response defined by a > 50% decrease in mean variant allele fraction. Patient response was assessed using RECIST 1.1; DCB was defined as complete or partial response or stable disease that lasted > 6 months. Progression-free survival and overall survival were recorded.Among 67 patients, 51 (76.1%) had > 1 variant detected at a variant allele fraction > 0.3% and thus were eligible for calculation of molecular response from paired baseline and 9-week samples. Molecular response values were significantly lower in patients with an objective radiologic response (log mean 1.25% v 27.7%, P < .001). Patients achieving a DCB had significantly lower molecular response values compared to patients with no durable benefit (log mean 3.5% v 49.4%, P < .001). Molecular responders had significantly longer progression-free survival (hazard ratio, 0.25; 95% CI, 0.13 to 0.50) and overall survival (hazard ratio, 0.27; 95% CI, 0.12 to 0.64) compared with molecular nonresponders.Molecular response assessment using circulating tumor DNA may serve as a noninvasive, on-therapy predictor of response to pembrolizumab-based therapy in addition to standard of care imaging in mNSCLC. This strategy requires validation in independent prospective studies." @default.
• W3136175145 created "2021-03-29" @default.
• W3136175145 creator A5015582820 @default.
• W3136175145 creator A5017846434 @default.
• W3136175145 creator A5018887779 @default.
• W3136175145 creator A5020805924 @default.
• W3136175145 creator A5029750461 @default.
• W3136175145 creator A5031689520 @default.
• W3136175145 creator A5038897823 @default.
• W3136175145 creator A5039249322 @default.
• W3136175145 creator A5048775652 @default.
• W3136175145 creator A5051074911 @default.
• W3136175145 creator A5054793665 @default.
• W3136175145 creator A5056098854 @default.
• W3136175145 creator A5061220833 @default.
• W3136175145 creator A5062034160 @default.
• W3136175145 creator A5065090056 @default.
• W3136175145 creator A5066351741 @default.
• W3136175145 creator A5078446172 @default.
• W3136175145 creator A5088542967 @default.
• W3136175145 creator A5089382639 @default.
• W3136175145 creator A5090256464 @default.
• W3136175145 date "2021-11-01" @default.
• W3136175145 modified "2023-10-17" @default.
• W3136175145 title "Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy" @default.
• W3136175145 cites W1864344361 @default.
• W3136175145 cites W2106511606 @default.
• W3136175145 cites W2527905628 @default.
• W3136175145 cites W2572174216 @default.
• W3136175145 cites W2604517038 @default.
• W3136175145 cites W2607977201 @default.
• W3136175145 cites W2770312776 @default.
• W3136175145 cites W2783576981 @default.
• W3136175145 cites W2796582438 @default.
• W3136175145 cites W2797855256 @default.
• W3136175145 cites W2800224623 @default.
• W3136175145 cites W2802607685 @default.
• W3136175145 cites W2804812017 @default.
• W3136175145 cites W2828180271 @default.
• W3136175145 cites W2884397450 @default.
• W3136175145 cites W2885775704 @default.
• W3136175145 cites W2886545851 @default.
• W3136175145 cites W2890203489 @default.
• W3136175145 cites W2891266481 @default.
• W3136175145 cites W2892640821 @default.
• W3136175145 cites W2898037973 @default.
• W3136175145 cites W2898241205 @default.
• W3136175145 cites W2904444972 @default.
• W3136175145 cites W2905051664 @default.
• W3136175145 cites W2906555241 @default.
• W3136175145 cites W2917463541 @default.
• W3136175145 cites W2925446385 @default.
• W3136175145 cites W2965346296 @default.
• W3136175145 cites W3007391700 @default.
• W3136175145 cites W3047097799 @default.
• W3136175145 cites W3049083268 @default.
• W3136175145 doi "https://doi.org/10.1200/po.20.00321" @default.
• W3136175145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8169078" @default.
• W3136175145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34095713" @default.
• W3136175145 hasPublicationYear "2021" @default.
• W3136175145 type Work @default.
• W3136175145 sameAs 3136175145 @default.
• W3136175145 citedByCount "35" @default.
• W3136175145 countsByYear W31361751452022 @default.
• W3136175145 countsByYear W31361751452023 @default.
• W3136175145 crossrefType "journal-article" @default.
• W3136175145 hasAuthorship W3136175145A5015582820 @default.
• W3136175145 hasAuthorship W3136175145A5017846434 @default.
• W3136175145 hasAuthorship W3136175145A5018887779 @default.
• W3136175145 hasAuthorship W3136175145A5020805924 @default.
• W3136175145 hasAuthorship W3136175145A5029750461 @default.
• W3136175145 hasAuthorship W3136175145A5031689520 @default.
• W3136175145 hasAuthorship W3136175145A5038897823 @default.
• W3136175145 hasAuthorship W3136175145A5039249322 @default.
• W3136175145 hasAuthorship W3136175145A5048775652 @default.
• W3136175145 hasAuthorship W3136175145A5051074911 @default.
• W3136175145 hasAuthorship W3136175145A5054793665 @default.
• W3136175145 hasAuthorship W3136175145A5056098854 @default.
• W3136175145 hasAuthorship W3136175145A5061220833 @default.
• W3136175145 hasAuthorship W3136175145A5062034160 @default.
• W3136175145 hasAuthorship W3136175145A5065090056 @default.
• W3136175145 hasAuthorship W3136175145A5066351741 @default.
• W3136175145 hasAuthorship W3136175145A5078446172 @default.
• W3136175145 hasAuthorship W3136175145A5088542967 @default.
• W3136175145 hasAuthorship W3136175145A5089382639 @default.
• W3136175145 hasAuthorship W3136175145A5090256464 @default.
• W3136175145 hasBestOaLocation W31361751451 @default.
• W3136175145 hasConcept C121608353 @default.
• W3136175145 hasConcept C126322002 @default.
• W3136175145 hasConcept C143998085 @default.
• W3136175145 hasConcept C207103383 @default.
• W3136175145 hasConcept C2776256026 @default.
• W3136175145 hasConcept C2776694085 @default.
• W3136175145 hasConcept C2777701055 @default.
• W3136175145 hasConcept C2778822529 @default.
• W3136175145 hasConcept C2779984678 @default.
• W3136175145 hasConcept C2780057760 @default.
• W3136175145 hasConcept C2781197716 @default.

• next